Akın KAYA, Numan NUMANOĞLU, Özkan YETKİN, İsmail SAVAŞ, Hacer SAVAŞ, Barış POYRAZ, Aydın ÇİLEDAĞ

The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer

“Epidermal growth factor receptor (EGFR)”ün, aşırı ekspresyonunun sıklıkla saptandığı küçük hücreli dışı akciğer kanseri (KHDAK)’nde, tümör progresyonunu belirleyen bir faktör olduğu bildirilmiştir. KHDAK’lı hastalarda serum EGFR düzeyinin klinik kullanılabilirliği tartışmalıdır. Bu çalışmada, KHDAK’lı hastalarda serum EGFR düzeylerinin ölçümü, serum EGFR düzeyi ile hastalık evresi, histolojik tip ve sağkalım süresi arasındaki ilişkinin belirlenmesi amaçlanmıştır. Serum EGFR düzeyi ELISA yöntemi ile ölçüldü. Çalışmaya 43 KHDAK’lı hasta ve 16 sağlıklı kişi alındı. Hastaların 29’u yassı hücreli karsinoma, 14’ü adenokarsinoma idi. Serum örnekleri tedaviden önce alındı. KHDAK’lı hastalarda ortalama serum EGFR düzeyi 17.53 ± 8.09 fmol/mL, sağlıklı grupta ise ortalama serum EGFR düzeyi 16.88 ± 7.08 fmol/mL olarak saptandı. Aradaki fark istatistiksel olarak anlamlı değildi (p= 0.912). Hastalık evresi, histolojik tip ile serum EGFR düzeyi arasında ilişki saptanmadı. Serum EGFR düzeyi ile sağkalım süresi arasında ilişki saptanmadı. Bu çalışmanın sonuçları, KHDAK’lı hastalarda serum EGFR düzeyinin bir tümör belirteci veya bir prognostik faktör olarak kullanılamayacağını göstermektedir. Bununla birlikte, bu sonuçları doğrulamak için geniş hasta gruplarında prospektif çalışmalara ihtiyaç vardır.

Küçük hücreli dışı akciğer kanseri olan hastalarda serum “epidermal growth factor receptor” düzeyinin prognostik önemi

Epidermal growth factor receptor (EGFR) has been implicated as a factor indicating tumour progression or as a prognostic factor in non-small cell lung cancer (NSCLC), in which its overexpression is often detected. The usefulness of identifying EGFR in serum from patients with NSCLC is controversial. This study was designed to identify serum EGFR levels in patients with NSCLC and to evaluate the relationship between serum EGFR levels and clinical stage, histological subtype and survival time. Serum EGFR levels were measured using quantitative enzyme-linked immunosorbent assay. The study included 43 patients with NSCLC and 16 healthy controls. The histological classification was 29 squamous carcinomas and 14 adenocarcinomas. Serum samples were collected before treatment.There was no difference between serum EGFR levels in patients with NSCLC (17.53 ± 8.09 fmol/mL) in comparison with those healthy controls (16.88 ± 7.08 fmol/mL; p= 0.912). There was also no difference in serum EGFR levels according to clinical stage or histological subtype. There was no relationship between serum EGFR levels and survival time in patients with NSCLC. The study’s results suggest that, the utility of serum EGFR levels in patients with NSCLC as a tumour marker or as a prognostic factor is limited. However, further prospective studies on a large number of patients will be necessary to confirm this study’s results.

PDF

___

1. Strauss GM. Prognostic markers in resectable non-small cell lung cancer. Oncol Clin North Am 1997; 11: 409-34.
2. Ulrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinas activity. Cell 1990; 61: 203-12.
3. Schlessinger J, Ulrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992; 9: 383-91.
4. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996; 7: 133-41.
5. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non small-cell lung cancers and adjacent benign lung. Cancer Res 1993; 53 (Suppl 10):2379-85.
6. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996; 32: 2070-4.
7. Sasaki H, Yukive H, Mizuno K, et al. Elevated serum epidermal growth factor receptor levels is correlated with lymph node metastasis in lung cancer. Int J Clin Oncol 2003; 8: 79-82.
8. Ambs KE, Takahahi A, Herring F, et al. Epidermal growth factor receptor in adenocarcinoma of the kidney. Urol Res 1989; 17: 251-4.
9. Choi JH, Oh JY, Ruy SK, et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 1997; 79: 1879-83.
10. Labbede O, Meziane MA, Rice TW. TNM staging of lung cancer. A quick reference chart. Chest 1999; 115: 232-5.
11. Mountain CF. Revision in the international staging system for staging lung cancer. Chest 1997; 111: 1710.
12. Haeder M, Rotsch M, Beppler G, et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 1988; 48: 1132-6.
13. Pavelic K, Banjac Z, Pavelic J, Sparenti S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993; 14: 1133-7.
14. Veale D, Kerr N, Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J cancer 1993; 68: 162-5.
15. Tateishi M, Ishida T, Mitsudomi T, et al. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of human lung. Cancer Res 1990; 50: 7077-80.
16. Czerniak B, Herz F, Wersto RP, et al. Quantification of oncogene products by computer-assisted image analysis and flow cytometry. J Histochem Cytochem 1990; 38:463-6
17. Partaner R, Hemminki K, Koskinen H, et al. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med 1994; 36: 1324-8.
18. Osaki T, Mitsudomi T, Oyama T, et al. Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest 1995; 108: 157-62.
19. Kandl H, Seymour L, Bezwoda WR. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early stage and advanced breast cancer. Br J Cancer 1994; 70: 739-42.
20. Okada N, Ohshio G, Yamaki KJ, et al. Elevated serum cerbB- 2 protein levels in patients with pancreatic cancer: Correlation to metastasis and shorter survival. Oncology 1995; 52: 392-6.
21. McKeinze SJ, De Sonbre KA, Bast BS, et al. Serum levels of HER-2 neu (c-erbB-2) correlate with over-expression of p185neu in human ovarian cancer. Cancer 1993; 71:3942-6.
22. Jacot W, Pujol JL, Boher JM, Lamy PJ. Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small cell lung cancer. Br J Cancer 2004; 91: 430-3.
23. Schneider J, Presek P, Braun A, et al. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. Br J Cancer 1999; 80: 1987-94.